Applied radiation oncology最新文献_第7页

Integrating MR-Guided Radiation Therapy Into Clinical Practice: Clinical Advantages and Practical Limitations 将核磁共振引导放射治疗纳入临床实践:临床优势与实践局限性

Applied radiation oncology Pub Date : 2021-09-01 DOI: 10.37549/aro1289

L. Tchelebi, Nicholas G Zaorsky, J. Rosenberg, K. Latifi, Sarah Hoffe

引用次数: 0

Improving Cancer Equity Through Advocacy 通过倡导改善癌症公平

Applied radiation oncology Pub Date : 2021-09-01 DOI: 10.37549/aro1286

G. Vidal

引用次数: 0

Time-Driven Activity-Based Costing of CT-Guided vs MR-Guided Prostate SBRT. 基于时间驱动的活动成本计算：CT 引导与 MR 引导的前列腺 SBRT 比较

Applied radiation oncology Pub Date : 2021-09-01 Epub Date: 2021-10-05

Neil R Parikh, Mary Ann Clark, Parashar Patel, Kayla Kafka-Peterson, Lalaine Zaide, Ting Martin Ma, Michael L Steinberg, Minsong Cao, Ann C Raldow, James Lamb, Amar U Kishan

{"title":"Time-Driven Activity-Based Costing of CT-Guided vs MR-Guided Prostate SBRT.","authors":"Neil R Parikh, Mary Ann Clark, Parashar Patel, Kayla Kafka-Peterson, Lalaine Zaide, Ting Martin Ma, Michael L Steinberg, Minsong Cao, Ann C Raldow, James Lamb, Amar U Kishan","doi":"","DOIUrl":"","url":null,"abstract":"Background and purpose: Stereotactic body radiation therapy (SBRT) has become a standard-of-care option for localized prostate cancer. While prostate SBRT has traditionally been delivered using computed-tomography-guided radiation therapy (CTgRT), MR-imaging-guided radiation therapy (MRgRT) is now available. MRgRT offers real-time soft-tissue visualization and ease of adaptive planning, obviating the need for fiducial markers, and potentially allowing for smaller planning target volume (PTV) margins. Although prior studies have focused on evaluating the cost-effectiveness of MRgRT vs CTgRT from a payor perspective, the difference in provider costs to deliver such treatments remains unknown. This study thus used time-driven activity-based costing (TDABC) to determine the difference in provider resources consumed by delivering prostate SBRT via MRgRT vs CTgRT.Methods: Data was collected from a single academic institution where prostate SBRT is routinely performed using both CTgRT and MRgRT. Five-fraction SBRT (40 Gy total dose) was assumed to be delivered through volumetric-modulated arc therapy for CTgRT patients, and through step-and-shoot, fixed-gantry intensity-modulated radiation therapy for MRgRT patients. Process maps were constructed for each portion of the radiation delivery process via interviews/surveys with departmental personnel and by measuring CTgRT and MRgRT treatment times. Prior to simulation, only CTgRT patients underwent placement of three gold fiducial markers. Personnel capacity cost rates were calculated by dividing total personnel costs by the annual minutes worked by a given personnel. Equipment costs included both an annualized purchase price and annual maintenance costs. Ultimately, the total costs of care encompassing personnel, space/equipment, and materials were aggregated across the entire chain of care for both CTgRT and MRgRT patients in a base case.Results: Direct costs associated with delivering a 5-fraction course of prostate SBRT were $1,497 higher with MRgRT than with CTgRT - comprised of personnel costs ($210 higher with MRgRT), space/equipment ($1,542 higher with MRgRT), and materials ($255 higher with CTgRT). Only CTgRT patients underwent fiducial placement, which accounted for $591. MRgRT patients were assumed to undergo both CT simulation (for electron density calculation) and MRI simulation, with the former accounting for $168. Mean time spent by patients in the treatment vault per fraction was 20 minutes (range 15-26 minutes) for CTgRT, and 31 minutes (range 30-34 minutes) for MRgRT. Patient time spent during fiducial placement (CTgRT only) was 60 minutes. Modifying the number of fractions treated would result in the cost difference of $1,497 (5 fractions) changing to $441 (1 fraction) or to $2,025 (7 fractions).Conclusion: This study provides an approximate comparison of the direct resources required for a radiat","PeriodicalId":72265,"journal":{"name":"Applied radiation oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8525878/pdf/nihms-1746515.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9100885","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Celebrating 10 Years 庆祝十周年

Applied radiation oncology Pub Date : 2021-09-01 DOI: 10.37549/aro1283

J. Suh

引用次数: 5

FLASH Stance — Updates in Ultrahigh Dose Rate Radiation Therapy FLASH立场——超高剂量率放射治疗的最新进展

Applied radiation oncology Pub Date : 2021-06-01 DOI: 10.37549/aro1279

M. B. Massat

引用次数: 0

Measured Distribution of Total Red Bone Marrow in Young Children 幼儿总红骨髓分布的测定

Applied radiation oncology Pub Date : 2021-06-01 DOI: 10.37549/aro1273

I. Abu-Gheida, Arwa A. Zaghal, L. Naffaa, P. Taddei